Insilico Medicine completes first-in-patient dose for its novel QPCTL inhibitor for solid tumors in collaboration with Fosun Pharma.

Insilico Medicine, a biotechnology company, has announced the initiation of the first in-patient dose for ISM8207, a potential small molecule inhibitor targeting QPCTL, in collaboration with Fosun Pharma. The Phase I clinical trial, conducted in China, aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ISM8207 in patients with lymphoma and other advanced solid tumors. ISM8207 has shown promising results in preclinical studies, demonstrating a significant anti-tumor effect and a favorable in vitro and in vivo profile. This collaboration represents an important milestone in the development of innovative therapeutics for patients. [Extracted from the article]